Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ERBB2 L869R |
Gene Variant Detail | |
Relevant Treatment Approaches | HER inhibitor (Pan) HER2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ERBB2 L869R | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vizimpro (dacomitinib) inhibited survival of transformed cells expressing ERBB2 (HER2) L869R in culture (PMID: 31588020). | 31588020 |
ERBB2 L869R | Advanced Solid Tumor | sensitive | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L869R were resistant to Tagrisso (osimertinib) in culture (PMID: 31588020). | 31588020 | |
ERBB2 L869R | Advanced Solid Tumor | resistant | HER2 Inhibitor | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L869R were resistant to Imbruvica (ibrutinib) in culture (PMID: 31588020). | 31588020 |
ERBB2 L869R | Advanced Solid Tumor | resistant | HER2 Inhibitor | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
ERBB2 L869R | colorectal adenocarcinoma | predicted - resistant | HER2 Inhibitor | Lapatinib + Trastuzumab | Case Reports/Case Series | Actionable | In a clinical case study, a colorectal carcinoma patient who initially achieved stable disease following treatment with Tykerb (lapatinib) and Herceptin (trastuzumab) developed secondary resistance, presenting with a brain metastasis, and ERBB2 (HER2) L869R was identified in the brain lesion (PMID: 29941010). | 29941010 |
ERBB2 L869R | breast cancer | sensitive | HER2 Inhibitor | Neratinib | Case Reports/Case Series | Actionable | In a Phase II trial, Nerlynx (neratinib) treatment resulted in a clinical benefit rate of 31% (5/16) in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, with 1 patient harboring ERBB2 (HER2) L869R achievd stable disease for 24 weeks or more (PMID: 28679771; NCT01670877). | 28679771 |
ERBB2 L869R | breast cancer | sensitive | HER2 Inhibitor | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nerlynx (neratinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957). | 28274957 |
ERBB2 L869R | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) inhibited survival of transformed cells expressing ERBB2 (HER2) L869R in culture (PMID: 31588020). | 31588020 |
ERBB2 L869R | lung adenocarcinoma | predicted - resistant | HER2 Inhibitor | Lapatinib | Case Reports/Case Series | Actionable | In a clinical case study, ERBB2 (HER2) L869R was identified in the lymph node metastasis from a lung adenocarcinoma patient that progressed on Tykerb (lapatinib) therapy (PMID: 27900369). | 27900369 |
ERBB2 L869R | Her2-receptor negative breast cancer | predicted - sensitive | HER2 Inhibitor | Neratinib | Case Reports/Case Series | Actionable | In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L869R (PMID: 29420467; NCT01953926). | 29420467 |
ERBB2 L869R | Advanced Solid Tumor | sensitive | HER2 Inhibitor | TH-4000 | Preclinical - Cell culture | Actionable | In a preclinical study, Tarloxotinib (TH-4000) inhibited survival of transformed cells expressing ERBB2 (HER2) L869R in culture (PMID: 31588020). | 31588020 |
ERBB2 L869R | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) L869R in culture (PMID: 31588020). | 31588020 | |
ERBB2 L869R | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Pyrotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pyrotinib inhibited survival of transformed cells expressing ERBB2 (HER2) L869R in culture (PMID: 31588020). | 31588020 |
ERBB2 L869R | Advanced Solid Tumor | resistant | HER2 Inhibitor | Sapitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L869R were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020). | 31588020 |
ERBB2 L869R | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Poziotinib (HM781-36B) inhibited survival of transformed cells expressing ERBB2 (HER2) L755S in culture (PMID: 31588020). | 31588020 |
ERBB2 L869R | breast cancer | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957). | 28274957 |
ERBB2 L869R | breast cancer | resistant | HER2 Inhibitor | Lapatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture, formed tumors and metastasized readily in xenograft animal models (PMID: 27900369). | 27900369 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02673398 | Phase II | Neratinib | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | Active, not recruiting | ||
NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Recruiting |